share_log

Biodexa Pharmaceuticals | EFFECT: Others

SEC announcement ·  Mar 28 18:11
Summary by Futu AI
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of March 27, 2024, at 5:00 P.M. This form is typically used by non-U.S. companies for registering securities for offering in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals, which is listed under the CIK number 0001643918 and has the file number 333-278040, has met the necessary regulatory requirements to proceed with its securities offering.
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of March 27, 2024, at 5:00 P.M. This form is typically used by non-U.S. companies for registering securities for offering in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals, which is listed under the CIK number 0001643918 and has the file number 333-278040, has met the necessary regulatory requirements to proceed with its securities offering.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.